SANTA BARBARA, CA—California-based public affairs firm Davies has hired Michael Wong as pharma/biotech practice leader. Wong will oversee the creation and implementation of strategic communications for pharmaceutical and biotech clients involved in crisis, high stake issues and key product and corporate initiatives that affect client reputation, revenue and business success.
Wong brings more than 20 years of experience as a business and counselor for pharmaceutical and biotech clients including Novartis, GlaxoSmithKline, Bayer, Merck, Medtronic and Boehringer Ingelheim. Most recently, Wong was healthcare practice leader for GCI Group and his career includes senior healthcare positions at leading agencies including Fleishman Hillard and Ruder Finn and serving as director of public affairs at Abbott.
The addition follows a 40 percent increase in healthcare billings at Davies and at a time when the new Obama administration is looking at healthcare reform.
"The question is who will benefit and who will lose from these reforms," says Wong. "For example, increased cost consciousness will tilt the treatment paradigm in favor of spending prevention dollars today, and away from costly long-term treatment plans. This leads to even greater price sensitivity and increased pressures on branded drugs to get on and stay on formulary and preferred status. This will be especially true for indications for cancer, HIV and rare diseases, where treatment costs are high."